Benznidazole
ApprovedSmall molecule
Benznidazole is one of 16 small molecule programs targeting Chagas disease. It is currently in Approved.
2
Indications
18
Total Trials
4
Active Trials
15
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Chagas Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Benznidazole
CCorestemchemon, Inc.
Approved
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Selenium
SSWOG Cancer Research Network
Phase 3
Fexinidazole
SanofiPhase 2
LXE408
NovartisPhase 2
E1224
DDrugs for Neglected Diseases
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chagas disease11 trials
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
Completed·IInstituto Nacional de Parasitologia Dr. Mario Fatala Chaben·Phase 3·NCT02386358·910 enrolled
Show 8 more trials
Population Pharmacokinetics of Benznidazole in Children With Chagas Disease
Completed·—·N/A·NCT00699387·37 enrolled
Treatment2 trials
Biomarkers1 trial
New Therapies and Biomarkers for Chagas Infection
Completed·—·Phase 2·NCT03981523·450 enrolled
2 more indications
Women of Reproductive Age1 trial
Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age
Active, not recruiting·—·Phase 3·NCT03672487·273 enrolled
Regulatory
FDA Approval Timeline[4]
Aug 29, 2017
BENZNIDAZOLE
NDA NDA209570
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Benznidazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- CCorestemchemon, Inc.